Endothelin B Receptor Antagonists
"Endothelin B Receptor Antagonists" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds and drugs that bind to and inhibit or block the activation of ENDOTHELIN B RECEPTORS.
| Descriptor ID |
D065131
|
| MeSH Number(s) |
D27.505.519.364.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Endothelin B Receptor Antagonists".
Below are MeSH descriptors whose meaning is more specific than "Endothelin B Receptor Antagonists".
This graph shows the total number of publications written about "Endothelin B Receptor Antagonists" by people in this website by year, and whether "Endothelin B Receptor Antagonists" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Endothelin B Receptor Antagonists" by people in Profiles.
-
Abdelsaid M, Ma H, Coucha M, Ergul A. Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes. Life Sci. 2014 Nov 24; 118(2):263-7.
-
Li W, Sachidanandam K, Ergul A. Comparison of selective versus dual endothelin receptor antagonism on cerebrovascular dysfunction in diabetes. Neurol Res. 2011 Mar; 33(2):185-91.
-
Kelly-Cobbs AI, Harris AK, Elgebaly MM, Li W, Sachidanandam K, Portik-Dobos V, Johnson M, Ergul A. Endothelial endothelin B receptor-mediated prevention of cerebrovascular remodeling is attenuated in diabetes because of up-regulation of smooth muscle endothelin receptors. J Pharmacol Exp Ther. 2011 Apr; 337(1):9-15.
-
Feng HQ, Weymouth ND, Rockey DC. Endothelin antagonism in portal hypertensive mice: implications for endothelin receptor-specific signaling in liver disease. Am J Physiol Gastrointest Liver Physiol. 2009 Jul; 297(1):G27-33.
-
Carneiro FS, Nunes KP, Giachini FR, Lima VV, Carneiro ZN, Nogueira EF, Leite R, Ergul A, Rainey WE, Clinton Webb R, Tostes RC. Activation of the ET-1/ETA pathway contributes to erectile dysfunction associated with mineralocorticoid hypertension. J Sex Med. 2008 Dec; 5(12):2793-807.
-
Sachidanandam K, Elgebaly MM, Harris AK, Hutchinson JR, Mezzetti EM, Portik-Dobos V, Ergul A. Effect of chronic and selective endothelin receptor antagonism on microvascular function in type 2 diabetes. Am J Physiol Heart Circ Physiol. 2008 Jun; 294(6):H2743-9.
-
Harris AK, Elgebaly MM, Li W, Sachidanandam K, Ergul A. Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. Am J Physiol Regul Integr Comp Physiol. 2008 Apr; 294(4):R1213-9.
-
Deschamps AM, Zavadzkas J, Murphy RL, Koval CN, McLean JE, Jeffords L, Saunders SM, Sheats NJ, Stroud RE, Spinale FG. Interruption of endothelin signaling modifies membrane type 1 matrix metalloproteinase activity during ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2008 Feb; 294(2):H875-83.
-
Elgebaly MM, Portik-Dobos V, Sachidanandam K, Rychly D, Malcom D, Johnson MH, Ergul A. Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes. Vascul Pharmacol. 2007 Aug-Sep; 47(2-3):125-30.